AIRE-2NCT06541938
AIRE-2 Device for Study of Breath Analysis in IBD
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 12 words Show 7 more changesShow less
- Primary endpoints: details revised at 1 of 1 entry
- Enrollment closed, study ongoing
- Primary completion date changed from estimate of Sep 30, 2027 to Nov 2, 2026
- Enrollment target: estimated 60 to confirmed 57
- Secondary endpoints revised (6)
- Site details revised
- Study description expanded, about 4 words
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Start date changed from estimate of Aug 15, 2024 to Aug 28, 2024
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Proof of data collection/Adherence to the protocol
Timeframe: 40 months
Secondary (6)
Comparison of positive breath between IBD and non-IBD controls
Prevalence of positive score with symptoms between IBD and non-IBD controls
Correlation of positive breath tests with severity of symptoms
Correlation of breath scores with food reported as being intolerant by the participants
Microbiome taxa
Show 1 moreShow less
Relative abundance of microbial metabolic pathways
Arms and interventions
Case - Inflammatory Bowel DiseaseExperimental
Patients with IBD, under clinical remission since more than 3 months, having at least one symptom
Control - Non-IBD (Healthy) ControlActive comparator
Non-IBD controls recruited from the household or general population, with no history of IBD or active gastrointestinal disease.
Dietary supplements: low FODMAP diet, Lactose Sachet, Fructose Sachet, Sorbitol Sachet, Inulin Sachet
Devices: AIRE-2 Portable breath analyzer
Sites
1 site in 1 country
- McMaster University Medical CentreHamilton, Ontario, Canada